Dosage and dosage of trametinib and dabrafenib

Targeted treatments for advanced melanoma block the activity of certain molecules within cancer cells that control cell growth. Two drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), can shrink tumors and help patients with advanced melanoma live longer. Through clinical trials, cancer researchers have found that combining dabrafenib and trametinib can treat advanced melanoma more effectively than either drug alone. The combination also produced less severe side effects than either drug alone.

Trametinib and dabrafenib are available as capsules and oral suspensions.

The recommended dose of trametinib in adult patients is 2 mg orally once daily. 2 mg. The recommended dose of trametinib in pediatric patients is based on body weight. Take trametinib at least 1 hour before or 2 hours after a meal.

Take trametinib at the same time every day about 24 hours apart. Take trametinib at least 1 hour before or 2 hours after a meal. Do not miss a dose of trametinib within 12 hours of your next dose. If you experience vomiting after taking trametinib, do not take additional doses. Take your next dose at the scheduled time.

The recommended dose of trametinib in adult patients is 150 mg (two 75 mg capsules) taken orally twice daily. The recommended dose of trametinib in pediatric patients is based on body weight. Take trametinib at least 1 hour before or 2 hours after a meal.

Take trametinib at the same time every day about 12 hours apart. Take trametinib at least 1 hour before or 2 hours after a meal. Do not miss a dose of trametinib within 6 hours of your next dose. If vomiting occurs after taking trametinib, do not take additional doses. Take your next dose at the scheduled time.

For patients with unresectable or metastatic melanoma or solid tumors, metastatic non-small cell lung cancer, or locally advanced or metastatic anaplastic thyroid cancer, the recommended duration of treatment is until disease progression or unacceptable toxicity. Recommended treatment duration for adjuvant therapy in melanoma is up to 1 year following disease recurrence or unacceptable toxicity. The recommended duration of treatment for pediatric patients with LGG is until disease progression or until unacceptable toxicity occurs.

Please note that in the actual application of trametinib and dabrafenib, patients should follow the doctor's instructions and prescriptions and adjust the dosage according to individual conditions. At the same time, you should pay close attention to the side effects and adverse reactions of drugs, report them to your doctor in time and seek help. If patients want to know more about trametinib and dabrafenib, please consult a professional medical consultant.